Phar­ma­Mar stock tanks af­ter PhI­II ovar­i­an can­cer study flops

Phar­ma­Mar’s late-stage test of Zep­syre (lur­binecte­din) has flunked the pri­ma­ry end­point on pro­gres­sion-free sur­vival for plat­inum-re­sis­tant ovar­i­an can­cer pa­tients. And the news tanked the Span­ish biotech’s share price, which plunged 32% on Fri­day as in­vestors re­treat­ed in the wake of the fail­ure.

Phar­ma­Mar had po­si­tioned the drug against topote­can or PLD (li­po­so­mal dox­oru­bicin), but re­searchers say that the PFS was the same. They did spot­light an im­proved safe­ty pro­file, though.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.